The aim of this paper was to investigate the impact of the Biofield Energy Treatment on the test formulation by focusing on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Kathryn Regina Sweas, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental group of Biofield Treated medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 53.5%, 127.9%, and 53.3% restoration of cell viability, at 0.1, 10, and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, UT-Med + BT-TI and BT-Med + BT-TI groups showed 42.4% (at 25 µg/mL) and 72.6% (at 0.1 µg/mL), restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 67.7% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 80.7%, 85%, and 93.7% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 65.8% (at 25 µg/mL) and 106.7% (at 50 µg/mL) in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 100.9% (at 0.1 µg/mL) and 91.2% (at 10 µg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 51.5% and 133.6% at 10 and 63 µg/mL, respectively in the BT-Med + BT-TI group compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 55.8% (at 10 µg/mL) and 43.8% (at 1 µg/mL) in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to the untreated in A549 cells. Serotonin level was significantly increased by 80%, 77.2%, and 58.7% in the BT-Med + BT-TI group at 10, 25, and 63 µg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 136.8%, 191.9%, and 165.8% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL compared to the untreated in MG-63 cells. Altogether, results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers also to protect and maintain the normal function of each vital organs. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, congenital heart disease, heart failure, arrhythmias, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, chronic bronchitis, asthma, cystic fibrosis, emphysema, osteoporosis, etc.
Comments: 12 Pages.
[v1] 2019-09-04 04:25:27
Unique-IP document downloads: 8 times
Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.
Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.